DE69525649T2 - Lamotrigin haltiges arzneimittel - Google Patents

Lamotrigin haltiges arzneimittel

Info

Publication number
DE69525649T2
DE69525649T2 DE69525649T DE69525649T DE69525649T2 DE 69525649 T2 DE69525649 T2 DE 69525649T2 DE 69525649 T DE69525649 T DE 69525649T DE 69525649 T DE69525649 T DE 69525649T DE 69525649 T2 DE69525649 T2 DE 69525649T2
Authority
DE
Germany
Prior art keywords
lamotrigine
pct
medicinal product
containing medicinal
date jun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69525649T
Other languages
German (de)
English (en)
Other versions
DE69525649D1 (de
Inventor
Philip Hiskett
Ann Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE69525649D1 publication Critical patent/DE69525649D1/de
Application granted granted Critical
Publication of DE69525649T2 publication Critical patent/DE69525649T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
DE69525649T 1994-12-07 1995-12-07 Lamotrigin haltiges arzneimittel Expired - Fee Related DE69525649T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9424766.5A GB9424766D0 (en) 1994-12-07 1994-12-07 Pharmaceutical composition
PCT/GB1995/002865 WO1996017611A1 (en) 1994-12-07 1995-12-07 Pharmaceutical composition comprising lamotrigine

Publications (2)

Publication Number Publication Date
DE69525649D1 DE69525649D1 (de) 2002-04-04
DE69525649T2 true DE69525649T2 (de) 2002-09-05

Family

ID=10765604

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525649T Expired - Fee Related DE69525649T2 (de) 1994-12-07 1995-12-07 Lamotrigin haltiges arzneimittel

Country Status (19)

Country Link
US (1) US5861179A (zh)
EP (1) EP0797441B1 (zh)
JP (1) JP2977284B2 (zh)
CN (1) CN1174505A (zh)
AT (1) ATE213633T1 (zh)
AU (1) AU696406B2 (zh)
BR (1) BR9509975A (zh)
CA (1) CA2207284A1 (zh)
CZ (1) CZ171797A3 (zh)
DE (1) DE69525649T2 (zh)
ES (1) ES2172600T3 (zh)
FI (1) FI972434A (zh)
GB (1) GB9424766D0 (zh)
HU (1) HUT77367A (zh)
NO (1) NO972623L (zh)
NZ (1) NZ296573A (zh)
PL (1) PL320560A1 (zh)
RU (1) RU2160106C2 (zh)
WO (1) WO1996017611A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
WO1998036737A1 (en) * 1997-02-25 1998-08-27 The Procter & Gamble Company Wet granulating method
EP1098636A1 (en) * 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
WO2000078907A1 (en) * 1999-06-21 2000-12-28 The Procter & Gamble Company Processes for making granular detergent in a fluidized bed granulator having recycling of improperly sized particles
WO2002068398A1 (en) 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US20050238724A1 (en) * 2002-04-23 2005-10-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1608342A2 (en) * 2003-03-21 2005-12-28 Ranbaxy Laboratories, Ltd. Stable lamotrigine pharmaceutical compositions and processes for their preparation
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
SI3395339T1 (sl) 2003-09-12 2019-08-30 Amgen, Inc, Hitrotopna formulacija, ki vsebuje cinakalcet HCL
MXPA06013870A (es) * 2004-05-31 2007-04-25 Senju Pharma Co Agente para visualizar tejido transparente.
WO2008104996A2 (en) * 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2011107944A2 (en) 2010-03-04 2011-09-09 Wockhardt Limited Modified release dosage form
EP3525792A4 (en) 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
CS234018B2 (en) * 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
AU635040B2 (en) * 1989-06-30 1993-03-11 Sumitomo Electric Industries, Ltd. Substrate having a superconductor layer
DE69207656T2 (de) * 1991-01-30 1996-10-17 Wellcome Found Wasserlösliche tabletten
CA2277722C (en) * 1991-11-22 2001-03-27 The Wellcome Foundation Limited Water dispersible tablets
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700114A1 (fr) * 1993-01-07 1994-07-08 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
FR2702149B1 (fr) * 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets

Also Published As

Publication number Publication date
ES2172600T3 (es) 2002-10-01
HUT77367A (hu) 1998-03-30
CA2207284A1 (en) 1996-06-13
CZ171797A3 (en) 1997-11-12
AU4121196A (en) 1996-06-26
EP0797441B1 (en) 2002-02-27
AU696406B2 (en) 1998-09-10
DE69525649D1 (de) 2002-04-04
GB9424766D0 (en) 1995-02-08
RU2160106C2 (ru) 2000-12-10
MX9704103A (es) 1997-09-30
EP0797441A1 (en) 1997-10-01
FI972434A (fi) 1997-06-09
PL320560A1 (en) 1997-10-13
NO972623L (no) 1997-08-06
BR9509975A (pt) 1998-06-09
JP2977284B2 (ja) 1999-11-15
NZ296573A (en) 1997-08-22
JPH10510255A (ja) 1998-10-06
NO972623D0 (no) 1997-06-06
FI972434A0 (fi) 1997-06-06
WO1996017611A1 (en) 1996-06-13
ATE213633T1 (de) 2002-03-15
US5861179A (en) 1999-01-19
CN1174505A (zh) 1998-02-25

Similar Documents

Publication Publication Date Title
DE69525649D1 (de) Lamotrigin haltiges arzneimittel
DZ1794A1 (fr) Nouvelle formule pharmaceutique.
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
BG101118A (en) Therapeutical compounds
DE69532580D1 (de) Neue antagonistische verbindungen
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
MX9400287A (es) Procedimiento para la preparacion de un medicamento util para el tratamiento de la enfermedad de parkinson
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
ZA965997B (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
AU7775398A (en) Novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions
AU5819394A (en) N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders
GEP20043377B (en) Pharmaceutical Complex
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee